Skip to main content
CING
NASDAQ Life Sciences

New Investor Group Acquires 19.99% Stake and Board Seats in Cingulate Inc. via $11M Private Placement

Analysis by Wiseek.ai
Sentiment info
Neutral
Importance info
9
Price
$7.19
Mkt Cap
$53.539M
52W Low
$3.2
52W High
$7.92
Market data snapshot near publication time

summarizeSummary

Falcon Creek Capital Advisor and its affiliates have acquired a 19.99% beneficial ownership in Cingulate Inc. through an $11 million private placement, gaining significant board representation and providing crucial capital to the company.


check_boxKey Events

  • Significant New Investor Group

    Falcon Creek Capital Advisor LLC, Falcon Creek Technology Fund I, LP, and Ginkgo Capital Global Fund SPC - Xtalpi AI Fund SP have collectively reported beneficial ownership of 19.99% of Cingulate Inc.'s outstanding common stock.

  • Substantial Capital Infusion

    The investor group acquired securities through a private placement totaling approximately $11.0 million, providing a significant capital boost to the company.

  • Board Representation and Influence

    The new investors are entitled to designate one director immediately and a second director upon stockholder approval, along with a non-voting board observer until the second director is appointed, indicating substantial governance influence.

  • Private Placement Details

    The acquisition involved 1,951,946 shares of common stock, 973 shares of Series A convertible preferred stock (convertible at $5.04/share), and warrants to purchase 1,868,482 shares of common stock (exercise price $5.04/share), priced at a discount to the current market price.


auto_awesomeAnalysis

This Schedule 13D filing reveals that Falcon Creek Capital Advisor LLC and its affiliated funds have acquired a significant 19.99% beneficial ownership stake in Cingulate Inc. through a private placement totaling over $11 million. This transaction, which includes common stock, convertible preferred stock, and warrants, is a critical financing event for Cingulate, following a series of capital-raising activities in recent weeks. The new investor group will gain substantial influence with the right to designate up to two directors to the Board and a non-voting observer, pending stockholder approval for the second director. While the offering is dilutive, securing this level of capital and a strategic investor with board representation is a vital step for the company's operational runway and future strategic direction, especially given its active pursuit of funding.

At the time of this filing, CING was trading at $7.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $53.5M. The 52-week trading range was $3.20 to $7.92. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed CING - Latest Insights

CING
Apr 28, 2026, 4:24 PM EDT
Filing Type: 424B3
Importance Score:
8
CING
Apr 14, 2026, 5:26 PM EDT
Filing Type: S-3
Importance Score:
8
CING
Mar 27, 2026, 4:01 PM EDT
Filing Type: 424B3
Importance Score:
8
CING
Mar 26, 2026, 4:24 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
CING
Mar 24, 2026, 5:14 PM EDT
Filing Type: 8-K
Importance Score:
9
CING
Mar 24, 2026, 5:13 PM EDT
Filing Type: 424B3
Importance Score:
9
CING
Mar 19, 2026, 6:00 PM EDT
Filing Type: S-3
Importance Score:
8
CING
Mar 18, 2026, 4:30 PM EDT
Filing Type: DEFA14A
Importance Score:
8
CING
Mar 18, 2026, 8:13 AM EDT
Filing Type: 10-K
Importance Score:
9
CING
Mar 18, 2026, 8:10 AM EDT
Filing Type: 8-K
Importance Score:
9